APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Fundamental Analysis
Canada - TSX:APLI - CA03783R1073 - Common Stock
0.015 CAD
0 (0%)
Taking everything into account, APLI scores 1 out of 10 in our fundamental rating. APLI was compared to 34 industry peers in the Pharmaceuticals industry. APLI has a bad profitability rating. Also its financial health evaluation is rather negative. APLI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
APLI had negative earnings in the past year.
In the past year APLI has reported a negative cash flow from operations.
APLI had negative earnings in each of the past 5 years.
APLI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -188.96%, APLI is not doing good in the industry: 94.12% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -188.96% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-211.81%
ROA(5y)-203.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
APLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APLI has about the same amount of shares outstanding.
APLI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for APLI has been reduced compared to a year ago.
2.2 Solvency
APLI has an Altman-Z score of -70.26. This is a bad value and indicates that APLI is not financially healthy and even has some risk of bankruptcy.
APLI's Altman-Z score of -70.26 is on the low side compared to the rest of the industry. APLI is outperformed by 97.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -70.26 |
ROIC/WACCN/A
WACC10.97%
2.3 Liquidity
APLI has a Current Ratio of 0.14. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.14, APLI is not doing good in the industry: 94.12% of the companies in the same industry are doing better.
APLI has a Quick Ratio of 0.14. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.14, APLI is not doing good in the industry: 94.12% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.14 |
3. Growth
3.1 Past
APLI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.00%, which is quite impressive.
APLI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -76.26%.
APLI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.17% yearly.
EPS 1Y (TTM)80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-76.26%
Revenue growth 3Y18.17%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 14.22% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49%
EPS Next 2Y22.07%
EPS Next 3Y14.22%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for APLI. In the last year negative earnings were reported.
Also next year APLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
APLI's earnings are expected to grow with 14.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.07%
EPS Next 3Y14.22%
5. Dividend
5.1 Amount
No dividends for APLI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:APLI (9/18/2025, 7:00:00 PM)
0.015
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.84%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap1.82M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -188.96% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-211.81%
ROA(5y)-203.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 17.52% | ||
| Cap/Sales | 1.92% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.14 | ||
| Altman-Z | -70.26 |
F-Score4
WACC10.97%
ROIC/WACCN/A
Cap/Depr(3y)78.19%
Cap/Depr(5y)66.91%
Cap/Sales(3y)1.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y49%
EPS Next 2Y22.07%
EPS Next 3Y14.22%
EPS Next 5YN/A
Revenue 1Y (TTM)-76.26%
Revenue growth 3Y18.17%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.05%
OCF growth 3YN/A
OCF growth 5YN/A